GSK of­fers en­cour­ag­ing da­ta on BC­MA-tar­get­ing armed an­ti­body, set­ting stage for a re­turn to late-stage can­cer stud­ies

Glax­o­SmithK­line $GSK is be­gin­ning to turn the cards it holds on an an­ti-BC­MA an­ti­body drug con­ju­gate, GSK2857916, its lead ef­fort in what is be­ing styled as an am­bi­tious new ef­fort to build an on­col­o­gy port­fo­lio in the wake of its 3-year-old deal to swap as­sets with No­var­tis.

In a Phase I/II study for mul­ti­ple myelo­ma, the con­ju­gate trig­gered a 60% re­sponse rate with a 7.9 month PFS rate among 35 heav­i­ly pre-treat­ed pa­tients. Corneal events and throm­bo­cy­tope­nia were com­mon side ef­fects in the da­ta, re­port­ed at At­lanta’s ASH con­fab.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER